US Dollar vs MXN

Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

Regístrate

0QQ6

Roche (0QQ6)

Roche Holding Ag

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:LSE:0QQ6

1 2 3 4 Próxima >

Fecha	Hora	Fuente	Título	Símbolo	Compañía
12/03/2025	01:00	UK Regulatory	Roche enters into an exclusive collaboration & licensing agreement with Zealand Pharma to co-develop and co-commercialise petrelintide as a potential foundational therapy for people with overweight and obesity	LSE:0QQ6	Roche Holding Ag
07/03/2025	00:00	UK Regulatory	Roche announces launch of Roche Genentech Innovation Center Boston based at Harvard’s Enterprise Research Campus in Allston	LSE:0QQ6	Roche Holding Ag
05/03/2025	00:00	UK Regulatory	FDA accepts supplemental Biologics License Application for Roche’s Gazyva/Gazyvaro for the treatment of lupus nephritis	LSE:0QQ6	Roche Holding Ag
02/03/2025	16:00	UK Regulatory	Phase III study shows Xolair may be more effective with fewer side effects than oral immunotherapy for the treatment of food allergies	LSE:0QQ6	Roche Holding Ag
28/02/2025	07:15	UK Regulatory	CHMP recommends EU approval of Roche’s Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma	LSE:0QQ6	Roche Holding Ag
20/02/2025	12:30	UK Regulatory	Roche unveils a new class of next-generation sequencing with its novel sequencing by expansion technology	LSE:0QQ6	Roche Holding Ag
12/02/2025	10:45	UK Regulatory	FDA approves Roche’s Evrysdi tablet as first and only tablet for Spinal Muscular Atrophy (SMA)	LSE:0QQ6	Roche Holding Ag
07/02/2025	02:45	UK Regulatory	New England Journal of Medicine publishes new data for Roche’s Gazyva/Gazyvaro which shows superiority over standard therapy in people with active lupus nephritis	LSE:0QQ6	Roche Holding Ag
04/02/2025	10:45	UK Regulatory	FDA approves Roche’s Susvimo as the first and only continuous delivery treatment for the leading cause of diabetes-related blindness	LSE:0QQ6	Roche Holding Ag
31/01/2025	10:45	UK Regulatory	Roche receives FDA approval for the first companion diagnostic to identify patients with HER2-ultralow metastatic breast cancer eligible for ENHERTU	LSE:0QQ6	Roche Holding Ag
30/01/2025	00:00	UK Regulatory	[Ad-hoc-Mitteilung gemäss Art. 53 KR] Roche erzielt starkes Jahresergebnis für 2024 mit Verkaufswachstum von 7%; drittes Quartal in Folge mit 9% Wachstum	LSE:0QQ6	Roche Holding Ag
30/01/2025	00:00	UK Regulatory	[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2024 results with 7% sales growth; fourth quarter marks third straight quarter of 9% growth	LSE:0QQ6	Roche Holding Ag
29/01/2025	00:00	UK Regulatory	Change to the Roche Enlarged Corporate Executive Committee	LSE:0QQ6	Roche Holding Ag
28/01/2025	00:00	UK Regulatory	Roche’s Itovebi demonstrated statistically significant and clinically meaningful overall survival benefit in a certain type of HR-positive advanced breast cancer	LSE:0QQ6	Roche Holding Ag
27/01/2025	00:00	UK Regulatory	Roche announces new results from EMBARK demonstrating significant sustained benefits of Elevidys in ambulatory individuals with Duchenne muscular dystrophy (DMD)	LSE:0QQ6	Roche Holding Ag
22/01/2025	00:00	UK Regulatory	Roche receives FDA clearance with CLIA waiver for cobas® liat molecular tests to diagnose sexually transmitted infections at the point of care	LSE:0QQ6	Roche Holding Ag
08/01/2025	00:10	UK Regulatory	Roche purchases shares in tender offer for Poseida Therapeutics, Inc.	LSE:0QQ6	Roche Holding Ag
19/12/2024	00:00	UK Regulatory	Roche’s Phase IIb study of prasinezumab missed primary endpoint, but suggests possible benefit in early-stage Parkinson’s disease	LSE:0QQ6	Roche Holding Ag
18/12/2024	00:00	UK Regulatory	Roche transforms mass spectrometry diagnostics with launch of cobas® Mass Spec solution	LSE:0QQ6	Roche Holding Ag
13/12/2024	00:10	UK Regulatory	Roche’s Vabysmo prefilled syringe (PFS) approved in the EU for three retinal conditions that can cause blindness	LSE:0QQ6	Roche Holding Ag
13/12/2024	00:00	UK Regulatory	Roche receives CE Mark for new and updated molecular cobas 6800/8800 systems, enhancing laboratory efficiency and testing capabilities	LSE:0QQ6	Roche Holding Ag
10/12/2024	00:00	UK Regulatory	New and updated data for Roche's fixed-duration Columvi and Lunsumio at ASH 2024 reinforce their potential to improve outcomes for people with lymphoma	LSE:0QQ6	Roche Holding Ag
09/12/2024	15:30	UK Regulatory	Roche commences tender offer for all shares of Poseida Therapeutics, Inc. for $9.00 per share in cash, plus a non-tradeable contingent value right for up to $4.00 per share in cash	LSE:0QQ6	Roche Holding Ag
08/12/2024	11:30	UK Regulatory	Five-year results confirm Roche’s Polivy combination therapy as new standard of care for previously untreated aggressive lymphoma	LSE:0QQ6	Roche Holding Ag
05/12/2024	00:00	UK Regulatory	FDA accepts supplemental Biologics License Application for Roche’s Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma	LSE:0QQ6	Roche Holding Ag
26/11/2024	00:10	UK Regulatory	Roche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologies	LSE:0QQ6	Roche Holding Ag
26/11/2024	00:00	UK Regulatory	Roche reports update on Phase III SKYSCRAPER-01 study results	LSE:0QQ6	Roche Holding Ag
05/11/2024	08:15	UK Regulatory	Roche to present new and encouraging long-term follow-up data across broad haematology portfolio at ASH 2024	LSE:0QQ6	Roche Holding Ag
31/10/2024	01:15	UK Regulatory	Roche presents new data at CTAD, demonstrating its growing momentum in diagnostics for Alzheimer’s disease	LSE:0QQ6	Roche Holding Ag
31/10/2024	01:00	UK Regulatory	New England Journal of Medicine publishes landmark phase III results for Roche’s Itovebi, showing more than doubling of progression-free survival in certain type of HR-positive advanced breast cancer	LSE:0QQ6	Roche Holding Ag

Showing the most relevant articles for your search:LSE:0QQ6

1 2 3 4 Próxima >

Barclays Bank Plc Point ...

LOG Commercial ON

Arista Networks

Gs Finance Corp Capped D...

Gs Finance Corp Capped P...

Apple Rush (PK)

DJ US Consumer Services ...

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones